[Painful peripheral neuropathy associated with voriconazole during the treatment of chronic cavitary pulmonary aspergillosis].
Chronic cavitary pulmonary aspergillosis requires a first-line prolonged treatment with itraconazole or voriconazole. We report a 71-year-old immunocompetent man with polyarteritis and history of multiple lung surgery procedures, who developed a peripheral axonal neuropathy 1 month after voriconazole therapy was started for a chronic cavitary pulmonary aspergillosis. After discontinuation of the treatment and a switch to posaconazole, the neuropathy partly improved. Three other cases of peripheral neuropathy with voriconazole have been already published, all reversible after voriconazole discontinuation.
Gendrot
A
A
Service des maladies infectieuses et tropicales, hôpital Côte-de-Nacre, CHU de Caen, avenue Côte-de-Nacre, BP 95182, 14033 Caen cedex 9, France.
de La Blanchardière
A
A
de La Gastine
B
B
Fromager
G
G
Massias
L
L
Verdon
R
R
D000368:Aged; D000935:Antifungal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001229:Aspergillosis, Allergic Bronchopulmonary / Q000188:drug therapy*; D002908:Chronic Disease; D006801:Humans; D008297:Male; D010146:Pain / Q000139:chemically induced / Q000503:physiopathology; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000503:physiopathology; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome; D014230:Triazoles / Q000009:adverse effects* / Q000627:therapeutic use*; D065819:Voriconazole
D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; C101425:posaconazole; D065819:Voriconazole